Dr. Devy A. Setyono, M.D
Rheumatology (Rheumatology Physician)
888 S King St
Honolulu, HI 96813
Who else practices at this address →
Honolulu County includes primary care (9% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 264
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
HI license MD241440 · PA license MD465812 -
Internal Medicine Physician
PA license MT206203
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Pali Momi Medical Center Aiea, HI
- Straub Clinic and Hospital Honolulu, HI
- Kapiolani Medical Center for Women & Children Honolulu, HI
Medical groups
- Phoenix Rehabilitation and Health Services Inc (2,800 clinicians)
- Straub Clinic and Hospital (419 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 264
- Services billed
- 11,313
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, romosozumab-aqqg, 1 mg | 21,000 | 26 |
| Injection, denosumab, 1 mg | 18,600 | 216 |
| Injection, golimumab, 1 mg, for intravenous use | 7,000 | 14 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 774 | 156 |
| Established patient office or other outpatient visit, 30-39 minutes | 540 | 353 |
| Injection of drug or substance under skin or into muscle | 293 | 196 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 222 | 141 |
| Injection, zoledronic acid, 1 mg | 155 | 31 |
| Dxa bone density measurement of hip, pelvis, spine | 149 | 149 |
| Established patient office or other outpatient visit, 20-29 minutes | 143 | 134 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $413 in total to this clinician.
| Genzyme Corporation | $125 |
|---|---|
| GlaxoSmithKline, LLC. | $125 |
| Novartis Pharmaceuticals Corporation | $85.90 |
| Sanofi-aventis U.S. LLC | $76.99 |
| Food and Beverage | $336 |
|---|---|
| Education | $76.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi-aventis U.S. LLC Jul 24, 2025 | Education KEVZARA · Rheumatology · in-kind | $76.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.